Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Feb 1.

Published in final edited form as: Br J Haematol. 2009 Nov 6;148(4):544–550. doi: 10.1111/j.1365-2141.2009.07982.x

2a. Time to first treatment (TFT) and percentage of abnormal nuclei by threshold. A higher percentage of abnormal nuclei, with either 13q-x1 or 13q-x2, is associated with a significantly shorter TFT (p<0.001, HR=4.4 (2.5–7.7)). Median time to treatment for % abnormal ≤ 65.5% and >65.5% was not reached and 3.4 years, respectively. The 5-year untreated rate for % abnormal ≤65.5% and >65.5% was 79% and 38%, respectively. 2b. Overall survival (OS) and percentage of abnormal nuclei by threshold. OS appears not to be affected by the percentage of abnormal nuclei (p=0.28, HR=1.5 (0.7–3.2)). Median OS for % abnormal ≤65.5 and % abnormal >65.5 are not reached and 9.3 years, respectively. The 5-year survival rate for % abnormal ≤65.5% and >65.5% was 88% and 83%, respectively.

2a. Time to first treatment (TFT) and percentage of abnormal nuclei by threshold. A higher percentage of abnormal nuclei, with either 13q-x1 or 13q-x2, is associated with a significantly shorter TFT (p<0.001, HR=4.4 (2.5–7.7)). Median time to treatment for % abnormal ≤ 65.5% and >65.5% was not reached and 3.4 years, respectively. The 5-year untreated rate for % abnormal ≤65.5% and >65.5% was 79% and 38%, respectively. 2b. Overall survival (OS) and percentage of abnormal nuclei by threshold. OS appears not to be affected by the percentage of abnormal nuclei (p=0.28, HR=1.5 (0.7–3.2)). Median OS for % abnormal ≤65.5 and % abnormal >65.5 are not reached and 9.3 years, respectively. The 5-year survival rate for % abnormal ≤65.5% and >65.5% was 88% and 83%, respectively.